133 related articles for article (PubMed ID: 11304643)
1. In vivo binding characteristics of phenytoin to serum proteins in monotherapy for adults with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
Am J Ther; 2000 Nov; 7(6):359-63. PubMed ID: 11304643
[TBL] [Abstract][Full Text] [Related]
2. In vivo binding characteristics of phenytoin to serum proteins in monotherapy pediatric patients with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Itokazu N; Sugimoto T
Int J Clin Pharmacol Ther; 2000 Jan; 38(1):25-9. PubMed ID: 10667833
[TBL] [Abstract][Full Text] [Related]
3. Serum protein binding kinetics of phenytoin in monotherapy patients.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
J Clin Pharm Ther; 1998 Oct; 23(5):361-5. PubMed ID: 9875684
[TBL] [Abstract][Full Text] [Related]
4. Effect of temperature on binding characteristics of phenytoin to serum proteins in monotherapy adult patients with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
Am J Ther; 2000 Jan; 7(1):11-5. PubMed ID: 11319568
[TBL] [Abstract][Full Text] [Related]
5. No gender effect on binding characteristics of phenytoin to serum proteins in monotherapy for adult patients with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
Am J Ther; 2000 Sep; 7(5):285-9. PubMed ID: 11317172
[TBL] [Abstract][Full Text] [Related]
6. Temperature effect on serum protein binding kinetics of phenytoin in monotherapy patients with epilepsy.
Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Todaka K; Mitsuyama Y
Eur J Pharm Biopharm; 1999 May; 47(3):295-8. PubMed ID: 10382115
[TBL] [Abstract][Full Text] [Related]
7. Effect of temperature on serum protein binding characteristics of phenytoin in monotherapy paediatric patients with epilepsy.
Kodama H; Kodama Y; Itokazu N; Shinozawa S; Kanemaru R; Sugimoto T
J Clin Pharm Ther; 2001 Jun; 26(3):175-9. PubMed ID: 11422600
[TBL] [Abstract][Full Text] [Related]
8. No effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy.
Kodama Y; Kodama H; Kuranari M; Tsutsumi K; Ono S; Fujimura A
J Clin Pharmacol; 1999 Oct; 39(10):1070-6. PubMed ID: 10516942
[TBL] [Abstract][Full Text] [Related]
9. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability.
Gatti G; Bartoli A; Marchiselli R; Michelucci R; Tassinari CA; Pisani F; Zaccara G; Timmings P; Richens A; Perucca E
Br J Clin Pharmacol; 1993 Dec; 36(6):603-6. PubMed ID: 12959280
[TBL] [Abstract][Full Text] [Related]
10. Gender- or age-related binding characteristics of valproic acid to serum proteins in adult patients with epilepsy.
Kodama Y; Kodama H; Kuranari M; Tsutsumi K; Ono S; Yukawa E; Fujimura A
Eur J Pharm Biopharm; 2001 Jul; 52(1):57-63. PubMed ID: 11438424
[TBL] [Abstract][Full Text] [Related]
11. Binding parameters of phenytoin during monotherapy and polytherapy.
Pospísil J; Perlík F
Int J Clin Pharmacol Ther Toxicol; 1992 Jan; 30(1):24-8. PubMed ID: 1348053
[TBL] [Abstract][Full Text] [Related]
12. Use of plasma unbound drug concentrations in adjusting phenytoin doses.
Bachmann K; Voeller K; Forney R
Ther Drug Monit; 1984; 6(2):173-8. PubMed ID: 6740736
[TBL] [Abstract][Full Text] [Related]
13. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
Sachdeo RC; Sachdeo SK; Levy RH; Streeter AJ; Bishop FE; Kunze KL; Mather GG; Roskos LK; Shen DD; Thummel KE; Trager WF; Curtin CR; Doose DR; Gisclon LG; Bialer M
Epilepsia; 2002 Jul; 43(7):691-6. PubMed ID: 12102670
[TBL] [Abstract][Full Text] [Related]
14. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients.
Deleu D; Aarons L; Ahmed IA
Arch Med Res; 2005; 36(1):49-53. PubMed ID: 15777995
[TBL] [Abstract][Full Text] [Related]
15. Phenytoin use in elderly nursing home residents.
Birnbaum AK; Hardie NA; Conway JM; Bowers SE; Lackner TE; Graves NM; Leppik IE
Am J Geriatr Pharmacother; 2003 Dec; 1(2):90-5. PubMed ID: 15555471
[TBL] [Abstract][Full Text] [Related]
16. Protein binding of valproic acid in Japanese pediatric and adult patients with epilepsy.
Kodama Y; Kodama H; Kuranari M; Tsutsumi K; Ono S; Yamaguchi T; Fujimura A
Am J Health Syst Pharm; 2002 May; 59(9):835-40. PubMed ID: 12004461
[TBL] [Abstract][Full Text] [Related]
17. Effect of sex on serum protein binding characteristics of phenytoin in pediatric patients with epilepsy.
Kodama H; Kodama Y; Itokazu N; Arimori K; Kanemaru R; Sugimoto T; Fujimura A
Am J Health Syst Pharm; 2000 Jun; 57(12):1144-7. PubMed ID: 10911514
[No Abstract] [Full Text] [Related]
18. Evaluation of phenytoin serum levels following a loading dose in the acute hospital setting.
Selioutski O; Grzesik K; Vasilyeva ON; Hilmarsson Á; Fessler AJ; Liu L; Gross RA
Seizure; 2017 Nov; 52():199-204. PubMed ID: 29073585
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of serum protein binding in epileptic children during sodium valproate maintenance therapy.
Yu HY
Ther Drug Monit; 1984; 6(4):414-23. PubMed ID: 6440321
[TBL] [Abstract][Full Text] [Related]
20. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.
Sachdeo R; Wagner ML; Sachdeo S; Shumaker RC; Lyness WH; Rosenberg A; Ward D; Perhach JL
Epilepsia; 1999 Aug; 40(8):1122-8. PubMed ID: 10448826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
